* Designed to help patients fall asleep, stay asleep * Merck's shares fall 1.1 percent to $45.47 By Toni Clarke May 20 (Reuters) - Merck & Co's experimental insomnia drug suvorexant appears genera…
Just days after raising more than $1B in its IPO, Quintiles announced Wednesday it signed a five-year clinical development agreement with Merck Serono. …
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. priced today a $6.5 billion public offering…
Merck Serono a division of German's Merck KGaA has announced a new fiveyear clinical development agreement with Quintiles. This strategic collaboration is the firstofitskind between a biopharma compan…
